Traders should be cautious of ZCMD's deteriorating fundamentals. The stock's recent Nasdaq compliance is a technical relief, but the core business is in decline. Monitor for signs of stabilization in the healthcare education segment and any new revenue streams. The high concentration of voting power with the CEO (99.5%) presents a governance risk.
Price Chart
Executive Summary
Zhongchao Inc. (ZCMD) reported a significant revenue decline of 28.3% YoY to $11.37M in 2025, driven by a strategic exit from its pharmaceutical sales business and reduced project collaborations. This follows a series of leadership changes, Nasdaq compliance issues resolved by a share consolidation, and ongoing financial losses. The company's core healthcare education business is under pressure, raising concerns about its turnaround strategy.
Key Facts
- Revenue declined 28.3% YoY to $11.37M in 2025, down from $15.86M in 2024 and $19.43M in 2023.
- Net loss widened significantly to $5.81M in 2025 from $0.27M in 2024.
- Company exited its pharmaceutical sales business (Xinjiang Pharmaceutical) in June 2025, which contributed $0.7M in 2025 revenue.
- Three senior officers (CMO, CSO, COO) resigned in March 2026, indicating leadership instability.
- Company regained Nasdaq compliance in March 2026 after a share consolidation, having previously fallen below the $1.00 minimum bid price.
- Gross margin declined to 45.0% in 2025 from 56.2% in 2024 due to increased project costs and pricing pressure.
Financial Impact
Revenue decreased by $4.49M, net loss increased by $5.54M compared to 2024.
Risk Factors
- Continued revenue and margin erosion in the core business.
- Leadership instability following multiple executive departures.
- High risk of future Nasdaq delisting if the share price remains volatile.
- Dependence on a few major customers for a significant portion of revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001213900-26-039923 |
| Document: ea028381501ex1-2.htm | 0001213900-26-039923 |
| Document: ea028381501ex4-1.htm | 0001213900-26-039923 |
| Document: ea028381501ex2-4.htm | 0001213900-26-039923 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 6-K | $1.08 $1.01 | ▲ +6.48% | ▲ +6.08% | $0.8770 (+18.80%) |
Jul 24, 2026 10w ago | 424B5 | $1.40 $1.28 | ▲ +8.57% | ▲ +8.94% | $0.8770 (+37.36%) |
Jun 9, 2026 16w ago | 6-K | $0.7831 $0.6900 | ▲ +11.89% | ▲ +14.30% | $0.8770 (−11.99%) |
Jun 9, 2026 16w ago | 6-K | $0.7831 $0.6900 | ▼ −11.89% | ▼ −14.30% | $0.8770 (+11.99%) |
Jun 5, 2026 17w ago | 6-K | $0.0260 $0.6498 | ▼ −2399.23% | ▼ −2398.66% | $0.8770 (−3273.08%) |
Jun 1, 2026 17w ago | 424B4 | $2.42 $0.8153 | ▲ +66.28% | ▲ +63.53% | $0.8770 (+63.73%) |
May 29, 2026 18w ago | EFFECT | $5.18 $0.8153 | ▲ +84.25% | ▲ +81.73% | $0.8770 (+83.06%) |
May 22, 2026 19w ago | F-1/A | $44.33 $2.42 | ▲ +94.55% | ▲ +96.28% | $0.8770 (+98.02%) |
May 7, 2026 21w ago | F-1 | $198.09 $134.85 | ▲ +31.92% | ▲ +34.19% | $0.8770 (+99.56%) |
Apr 3, 2026 26w ago | 20-F | $159.96 $186.93 | ▼ −16.86% | ▼ −12.74% | $0.8770 (+99.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access